Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Inovio Pharmaceuticals

Ocugen, Inc.

Pharmaceutical stocks have been relatively subdued in the last 12 months. During this period, the S&P 500 Pharmaceutical Industry index has trended higher by 3.5%.

3 Sorry Pharma Stocks to Sell in February Before It's Too Late

1 Reason to Buy Novavax in 2023 and 2 Reasons to Sell

Despite being one of the few authorized COVID-19 vaccine makers in the United States, Novavax's (NVAX) vaccine struggles for market share.

Novavax (NVAX) COVID Jab Aids Growth, Overdependence a Challenge (revised)

BioNTech SE

Moderna

Pfizer

An FDA advisory committee unanimously votes in favor of using the same COVID-19 vaccine strain composition for primary series and booster doses.

FDA Panel Endorses Simplification of COVID-19 Vaccine Strategy

Novavax plans to update its Covid vaccine for new variants, and NVAX stock outperformed its vaccine stock rivals. The post Novavax Jumps After Pledging To Update Its Covid Shot; Pfizer, Moderna Slip appeared first on Investor's Business Daily.

Novavax Jumps After Pledging To Update Its Covid Shot; Pfizer, Moderna Slip

Beam Therapeutics

Maravai LifeSciences Holdings

These beaten-down stocks could be poised for major rebounds.

3 Great Growth Stocks Down 20% or More to Buy Now

Novavax (NVAX) COVID Jab Aids Growth, Overdependence A Woe

If you want to invest in volatile stocks, a certain strategy can minimize your overall risk.

This Investment Strategy Would Have Reduced Your Novavax Losses by 20% Last Year

Upstart Holdings

Petco Health and Wellness

Exceptionally high short interest in these innovative and transformative businesses may lead to a short squeeze.

3 Remarkable Stocks That Can Burn Short-Sellers Big-Time in 2023

Can Novavax still win over the long term?

Here's the Worst Mistake Novavax Investors Can Make in 2023

Novavax's (NVAX) COVID-19 vaccine gets approval in South Korea as a booster dose in adults 18 years and older.

Novavax (NVAX) Gets Nod for COVID-19 Booster Jab in South Korea

GAITHERSBURG, Md. , Jan. 18, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that partner SK bioscience has received expanded manufacturing and marketing approval from the Korean Ministry of Food and Drug Safety (KMFDS) for Nuvaxovid™ (NVX-CoV2373) for use as a booster for active immunization to prevent COVID-19 in adults aged 18 and older.

Novavax Nuvaxovid COVID-19 Vaccine Approved in South Korea as an Adult Booster

Anavex Life Sciences

MannKind

All three stocks have promising therapies that could drive revenue in the coming years.

3 Biotech Stocks Under $15 Worth a Second Look in 2023

Teladoc

Any bit of good news could send these stocks soaring.

2 Down-on-Their-Luck Stocks That Could Go Parabolic

Is Novavax stock a buy or a sell after snagging Harmony Bio's chief executive, John Jacobs? Is NVAX stock a buy or a sell right now?

Novavax Snags New CEO From Harmony — But Is Novavax Stock A Buy Or A Sell?

Novavax stock would likely have fallen in 2022 even in a bull market.

Don't Blame the Bear Market for This Growth Stock's Jaw-Dropping Sell-Off

With This Big Transition Ahead, Is Novavax a Buy?

Lovesac Company

These innovative growth stocks have the tailwinds necessary to deliver triple-digit returns for their shareholders by mid-2024.

Nasdaq Bear Market: 3 Remarkable Growth Stocks That Can Double Your Money in 18 Months

Novavax (NVAX) appoints John C. Jacobs as its new president and chief executive officer, effective Jan 23, 2023.

Novavax (NVAX) Names John Jacobs as New CEO, Shares Rise

After struggling mightily since the tail end of 2021, Novavax (NASDAQ: NVAX ) finally gave embattled stakeholders something to cheer about. On Monday, NVAX stock popped dramatically higher on the news that current CEO Stanley Erck will retire.

NVAX Stock Alert: What to Know as Novavax Names New CEO

Affirm

Carvana

Opendoor

Investors looking forward to a better year for the stock market might figure the worst performers will deliver the best gains, but history indicates otherwise.

These Stocks Were 2022's Worst. That Doesn't Make Them Buys.

Shares of Novavax Inc. NVAX, +10.34% were up about 9% in trading on Monday after the company said John Jacobs will take over as president and CEO on Jan. 23. Jacobs, the former president and CEO of Harmony Biosciences Holdings Inc. HRMY, -14.57% , will replace Stanley Erck, who will continue to advise for the company into 2024.

Novavax's stock rallies after the company names new CEO

Current President & CEO Stanley C. Erck will retire effective January 23 with plans to support the leadership transition in an advisory capacity Novavax is well-positioned to execute on its strategy, with global authorizations for its COVID-19 vaccine and continued clinical pipeline development GAITHERSBURG, Md.

Novavax Names John C. Jacobs as New President & Chief Executive Officer

Could the biotech be the ultimate contrarian buy of 2023?

Is Novavax Stock a Bargain After Falling More Than 90% From Its High?

Novavax (NVAX) initiates a mid-stage study evaluating its COVID-19-Influenza combination and standalone influenza vaccines in adults aged 50 through 80 years.

News for Novavax Stock (NVAX)